Grail’s shares plummeted more than 45% after-hours Thursday as the medtech revealed a major National Health Service (NHS) ...

This story was originally published on PharmaVoice. To receive daily news and insights, subscribe to our free daily PharmaVoice newsletter. When Sarepta Therapeutics revealed this month that a ...

Two of the most closely watched Alzheimer clinical trials of the decade have delivered a sobering verdict: GLP-1 drugs that revolutionized diabetes and weight loss did not slow the disease’s ...

Cassava Sciences has given up on simufilam in Alzheimer’s disease. Months after seeing one phase 3 trial fail, the biotech is planning to stop development altogether after chalking up another ...

Please provide your email address to receive an email when new articles are posted on . None of the eligible trials received a “good” diversity rating for race and ethnicity. Access-related barriers ...

Novo Nordisk encountered a significant disappointment this week when the company announced that late-stage trials of Rybelsus failed to demonstrate effectiveness in slowing cognitive decline among ...

Thirty-two percent of confirmatory trials demonstrated an overall survival benefit when the drug was converted from accelerated approval to regular approval. Confirmatory trials for cancer drugs that ...

A new study finds just 6% of clinical trials used to approve new drugs in the U.S. reflect the country's racial and ethnic makeup, with an increasing trend of trials underrepresenting Black and ...

LONDON/COPENHAGEN (Reuters) -Novo Nordisk's closely-watched Alzehimer's trials - which failed on Monday to show it can slow the disease’s progression - were always a long-shot, although they had ...

A retrospective analysis found that strategic decisions and recruitment challenges were leading contributors to head and neck squamous cell carcinoma trial failures, accounting for 29.5% and 26.0% of ...

Diversity in clinical trials matters for drug safety and efficacy—and for future medical advancements. Clinical trial ...